17th September 2020 - Clinical trials and treatments in COVID-19
Event Date: On Demand
Duration: approximately 120 minutes
Presentation: "Clinical trials and treatments in COVID-19"
*To view the webinar on-demand, please register at the bottom of the page*
- Innovative Trial Designs: the what, why and when - Katherine Lee
- The ASCOT study - Steven Tong
- Where are we at with vaccine development? - Paul Griffin
- Management pearls - The Australian COVID-19 experience - Megan Rees and Nenad Macesic
This webinar aims to bring members up to date with the latest progress in Australian and New Zealand clinical trials, vaccines and management of patients with COVID-19. Local experts will walk us through new ways of performing clinical research in a pandemic world whilst also updating us on where we are at with vaccine development. Finally we will hear how our front line workers are managing patients with COVID-19 including the role of newly emerging treatments.
Katherine Lee, Murdoch Children's Research Institute
Katherine is a senior biostatistician at the Murdoch Children’s Research Institute and is the Associate Director: Biostatistics in the Melbourne Children’s Trials Centre at the Royal Children’s Hospital. She also holds an honorary appointment at the University of Melbourne. She has over 15 years' experience in the design, planning and analysis of randomised trials and observational studies, including a number of multisite, international and adaptive trials. Her methodological interests are in multiple imputation for dealing with missing data and adaptive and platform trials.
Steven Tong, Royal Melbourne Hospital
Steven Tong is an infectious diseases physician at the Royal Melbourne Hospital. He is Co-Chair of Translational and Clinical Research and Co-Chair Indigenous Health at the Doherty Institute for Infection and Immunity. He chairs the Australasian Society for Infectious Diseases Clinical Research Network. He leads the Australasian COVID-19 Trial (ASCOT).
Paul Griffin, Mater Health
Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Conjoint Associate Professor at the University of Queensland School of Medicine. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine. Paul is the Principal Investigator and Medical Director at Nucleus Network; a specialized contract research organisation specializing in early and late phase clinical trials where he has been the principal investigator on in excess of 120 clinical trials, predominantly in Infectious Diseases including novel vaccines. Finally, as a Clinical Microbiologist he maintains an active interest in diagnostic microbiology.
Nenad Macesic, Alfred Hospital
Dr. Nenad Macesic is an Infectious Diseases physician at the Alfred Hospital in Melbourne with a clinical focus on infections in immunocompromised patients. During the pandemic, he has cared for COVID patients in a variety of acute and subacute settings and has been the co-ordinator of COVID clinical management guidelines for the Alfred Hospital. He currently holds an NHMCR Emerging Leader fellowship and conducts research on genomics of multi-drug resistant Gram negative bacteria.
Megan Rees, Royal Melbourne Hospital
Megan Rees is a Respiratory Physician at the Royal Melbourne Hospital and Senior Lecturer at the University of Melbourne. Her PhD was a proteomic study of Mycobacterium tuberculosis. Megan is co-chair of the Respiratory Infectious Diseases special interest group of the TSANZ, she is a member of the RACP COVID expert advisory group and the National COVID-19 Clinical Evidence Taskforce Disease-Modifying Treatment and Chemo-prophylaxis Panel.
Please note that upon completing registration, you will receive an e-mail containing a link to the recording that you may then view on demand.
|Category||Fee (excl. GST)|
Please contact the TSANZ Office on +61 2 9222 6200 or e-mail email@example.com
Free for TSANZ Members; Non-Members $20